A Phase 1 interventional study of JMT206 injection and Semaglutide injection in Valid MeSH Conditiongs, sponsored by Shanghai JMT-Bio Inc.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Shanghai JMT-Bio Inc. · Phase 1, Interventional, and Treatment
Use these resources to provide understandable information about this study to patients, families, and health care providers:
Exclusion Criteria:
1) Those known to have a history of allergy to any component or related preparations in the investigational drug and its excipients, or have severe allergic diseases or allergic constitution; 2) Participants with a history of diabetes mellitus or hypoglycemic episodes; 3) Obesity is related to medication or diseases; Or weight gain caused by non-fat content; or monogene mutationsobesity; 4) History of weight loss surgery and/or treatment within the past year; 5) History of severe gastrointestinal disease or gastrointestinal surgery, clinically significant gastric emptying abnormalities, or long-term use of medications directly affecting gastrointestinal motility; 6) Having comorbidities known to affect skeletal muscle proteins; 7) A history of acute or chronic pancreatitis; 8) Acute gallbladder disease within one year prior to screening; 9) Previous or family history of medullary thyroid carcinoma or type 2 endocrine adenomatosis; 10) Severe cardiovascular or cerebrovascular events within 6 months prior to screening; 11) Any type of treated or untreated malignant tumor within 5 years prior to screening; 12) History of severe mental illness; 13) Use of drugs or products that may cause weight changes within 3 months prior to screening; 14) Use of drugs or products affecting skeletal muscle synthesis within 3 months prior to screening; 15) Participants deemed otherwise unsuitable for this trial by the investigator.
-
JMT206 injection dose 2 administered subcutaneously (SC) once a week
Drug: JMT206 injection
JMT206 injection dose 3 administered subcutaneously (SC) once a week
Drug: JMT206 injection
JMT206 injection dose 1 administered subcutaneously (SC) once a week. Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased.
Drug: JMT206 injection · Combination Product: Semaglutide injection
JMT206 injection dose 2 administered subcutaneously (SC) once a week. Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased.
Drug: JMT206 injection · Combination Product: Semaglutide injection
JMT206 injection dose 3 administered subcutaneously (SC) once a week. Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased
Drug: JMT206 injection · Combination Product: Semaglutide injection
Placebo administered subcutaneously (SC) once a week
Drug: Placebo injection
Placebo administered subcutaneously (SC) once a week. Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased.
Combination Product: Semaglutide injection · Drug: Placebo injection
JMT206 injection dose 1 administered subcutaneously (SC) once a week
Drug: JMT206 injection
JMT206 injection administered subcutaneously (SC) once a week
Semaglutide administered subcutaneously once a week, starts from lower dose and is gradually increased.
Placebo administered subcutaneously (SC) once a week.
Incidence of Adverse Events (AE) assessed by CTCAE v6.0
Time frame: Baseline through week 19
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai JMT-Bio Inc.